The clinical study of pasting "Wei Tan Wai Fu Fang" on acupuncture point to treat patients suffering postoperative gastroparesis of digestive cancer

ISRCTN ISRCTN18291857
DOI https://doi.org/10.1186/ISRCTN18291857
Secondary identifying numbers D131100002213003
Submission date
28/08/2013
Registration date
25/10/2013
Last edited
17/12/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
We are carrying out a study to find out the effect of "Wei Tan Wai Fu Fang" on the symptoms of postoperative gastroparesis (abnormal functioning of the stomach after surgery) in digestive cancer. We want to see whether it is effective to paste "Wei Tan Wai Fu Fang" on acupuncture point when treating postoperative gastroparesis of digestive cancer.

Who can participate?
The study aims to recruit adult men and women suffering from postoperative gastroparesis of digestive cancer whose local identification of abdomen is cold pattern ,which means this kind of patient prefers heat to cold ,likes hot food and hates cold ones.

What does the study involve?
Over a period of one and a half years participants will be invited to have Wei Tan Wai Fu Fang or placebo (dummy) on two acupuncture points every morning . This can be had along with the routine treatment . At the end of the study , we will find out the effects of having Wei Tan Wai Fu Fang on acupuncture points when treating postoperative gastroparesis of digestive cancer.

What are the possible benefits and risks of participating?
The results of the study are likely to find out a new way to treat the symptoms of postoperative gastroparesis of digestive cancer. The main risk of this study is unknown allergy because Wei Tan Wai Fu Fang includes many Chinese medicinal herbs which are potential allergens. If this occurs, the volunteer can quit the study .

Where is the study run from?
The study is run from the following hospitals in China:
1. Dongfang Hospital affiliated to Beijing University of Chinese Medicine
2. Chinese PLA General Hospital
3. Peking University People's Hospital
4. Cancer Institute and Hospital Chinese Academy of Medical Sciences (CAMS)

When is study starting and how long is it expected to run for?
The recruitment started in mid-2013. Participants will be enrolled in the study for a year and a half.

Who is funding the study?
Beijing Municipal Science and Technology Commission, China.

Who is the main contact?
Dr Kaiwen Hu
wulq1211@163.com

Contact information

Dr Hu Kaiwen
Scientific

No. 6, District 1, Fangxingyuan, Fangzhuang, Fengtai District, Beijing, P.R. China
Beijing
100078
China

Study information

Study designDouble-blind randomised parallel-group multi-site trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleThe clinical study of pasting "Wei Tan Wai Fu Fang" on acupuncture point to treat patients suffering postoperative gastroparesis of digestive cancer: a double-blind randomised parallel group multi-site trial
Study acronymWTWFF
Study objectivesIt might be effective to paste "Wei Tan Wai Fu Fang" on acupuncture point when treating postoperative gastroparesis of digestive cancer.
Ethics approval(s)Clinical Research Ethics Committee Office of Dongfang Hospital Affiliated to Beijing University of Chinese Medicine
Health condition(s) or problem(s) studiedPostoperative gastroparesis of digestive cancer
InterventionThis is a double-blind randomised parallel group multi-site trial.120 volunteers are divided into two groups by a certain people who won’t participate in the clinical observation so as to ensure the double-blind observation.
Patients in Group 1 will be treated with “Wei Tan Wai Fu Fang” as well as conventional therapy (parenteral nutrition, gastrointestinal decompression, prokinetic drugs).
Patients in Group 2. will be treated with the placebo of “Wei Tan Wai Fu Fang” and conventional therapy.
Intervention typeOther
Primary outcome measureClinical efficiency: It is effective when a patient restores motility in two weeks or he is able to take in nutrients by himself after unplugging the nasogastric tube. It is measured by the Gastroparesis Cardinal Symptom Index.
Secondary outcome measures1. Gastroparesis symptom score
2. The amount of stomach drainage or vomiting
Outcomes will be recorded on the 1st, 3rd, 5th, 7th and 14th day of the treatment.
Overall study start date01/07/2013
Completion date31/12/2014

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants120
Total final enrolment128
Key inclusion criteria1. Aged 18 years or older
2. Patients suffering postoperative gastroparesis of digestive cancer
3. Local identification is cold pattern. This means that, this kind of patients prefer warm to cold, likes hot food and hates cold one)
Key exclusion criteria1. Gastroscope or gastrointestinal contrast detection indicates that the patient is suffering mechanical intestinal obstruction
2. Patients with other diseases such as diabetes or scleroderma ,which may cause gastroparesis
3. Patients taking drugs like morphine and atropine which affect the function of gastic smooth muscle
4. Patients having rash, papules, erythema, herpes, exfoliative dermatitis or ulcerative dermatitis in the abdominal skin
Date of first enrolment01/07/2013
Date of final enrolment31/12/2014

Locations

Countries of recruitment

  • China

Study participating centres

Dongfang Hospital
No. 6, District 1
Fangxingyuan
Fangzhuang
Fengtai District
Beijing
100078
China
Chinese PLA General Hospital
28 Fuxing Road
Beijing
100853
China
Peking University People's Hospital
11 Xizhimen S St Xicheng
Beijing
-
China
Cancer Institute and Hospital Chinese Academy of Medical Sciences (CAMS)
No.17 Panjiayuannanli
Chaoyang District
P.O. Box 2258
Beijing
100021
China

Sponsor information

Beijing University of Chinese Medicine (China)
University/education

c/o Kaiwen Hu
11 N. 3rd Ring Rd E
Chaoyang
Beijing
100078
China

ROR logo "ROR" https://ror.org/05damtm70

Funders

Funder type

Government

Beijing Municipal Science and Technology Commission (China)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 23/12/2017 17/12/2020 Yes No

Editorial Notes

17/12/2020: Publication reference and total final enrolment added.